Author Archives: Natalie Themm
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
SINTX 2025 Highlights
As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year.
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
Bloom Surgical: 2025 Year In Review
2025 marked a year of significant progress of reached milestones and successes for Bloom Surgical
Adam Barker, PhD, Named President and Chief Operations Officer of ARUP Reference Business Unit
A microbiologist, Adam Barker, PhD, was ARUP’s chief scientific officer and director of Research and Development before being named chief operations officer—now adds Reference Business Unit president to his title.
Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
Merit Medical’s Fred Lampropoulos Honored by Nasdaq
Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million
Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million
